LpD3.5 Intervention Study in Older Adults- LISA-I Trial
Key claim: The LISA-I trial will test whether 60-day supplementation with heat-inactivated postbiotic LpD3.5 reduces gut permeability and inflammation and improves microbiome and cognitive outcomes in older adults with mild cognitive impairment.
Abstract
This randomized placebo-controlled clinical study, called the LpD3.5 Intervention Study in Older Adults (LISA), aims to evaluate whether a heat-inactivated postbiotic of human origin (LpD3.5) can serve as a non-pharmacological intervention to reduce gut permeability and inflammation in older adults with mild cognitive impairment (MCI). The study will assess the effects of LpD3.5 supplementation on markers associated with gut health, inflammation, microbiome composition, and cognitive function.
Participants aged 60 years or older with clinically diagnosed MCI will receive either LpD3.5 capsules or placebo capsules for 60 days, followed by a 30-day follow-up period. Biological samples and clinical assessments will be collected to evaluate changes in gut permeability, inflammatory markers, microbiome characteristics, and cognitive outcomes. The findings from this study may provide insight into the potential role of postbiotics as a dietary intervention to improve gut health and related outcomes in older adults with MCI.
Why this matters
LISA-I is one of the first registered human trials to test a heat-inactivated postbiotic specifically for the gut-barrier–inflammation–cognition axis in older adults with MCI, moving the postbiotic-for-aging trend from rodent and mechanistic work toward a clinical readout. Because it is a protocol rather than a results paper, it belongs to the trend-momentum column, not the evidence column — the divergence between growing trial activity and still-absent efficacy data is itself the signal to track.